etonogestrel - Profile

What are the generic drug sources for etonogestrel and what is the scope of patent protection?

Etonogestrel is the generic ingredient in two branded drugs marketed by Organon and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Etonogestrel has one hundred and five patent family members in thirty-five countries.

Summary for etonogestrel

International Patents:	105
US Patents:	4
Tradenames:	2
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for etonogestrel

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for etonogestrel

Constraining patent/regulatory exclusivity:

EXTENSION OF THE DURATION OF USE FROM 3 YEARS TO 5 YEARS

Dosage:

IMPLANT;IMPLANTATION

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Paragraph IV (Patent) Challenges for ETONOGESTREL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NEXPLANON	Implant	etonogestrel	68 mg	021529	1	2024-12-31

US Patents and Regulatory Information for etonogestrel

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Organon	IMPLANON	etonogestrel	IMPLANT;IMPLANTATION	021529-001	Jul 17, 2006		DISCN	No	No			Y
Organon	NEXPLANON	etonogestrel	IMPLANT;IMPLANTATION	021529-002	May 13, 2011		RX	Yes	Yes			Y
Organon	NEXPLANON	etonogestrel	IMPLANT;IMPLANTATION	021529-002	May 13, 2011		RX	Yes	Yes			Y
Organon	NEXPLANON	etonogestrel	IMPLANT;IMPLANTATION	021529-002	May 13, 2011		RX	Yes	Yes			Y
Organon	NEXPLANON	etonogestrel	IMPLANT;IMPLANTATION	021529-002	May 13, 2011		RX	Yes	Yes			Y

Expired US Patents for etonogestrel

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Organon	IMPLANON	etonogestrel	IMPLANT;IMPLANTATION	021529-001	Jul 17, 2006
Organon	IMPLANON	etonogestrel	IMPLANT;IMPLANTATION	021529-001	Jul 17, 2006

International Patents for etonogestrel

Country	Patent Number	Title	Estimated Expiration
South Korea	101269271
Canada	2636145
Russian Federation	2007132007	АППЛИКАТОР ДЛЯ ВВЕДЕНИЯ ИМПЛАНТАТА
China	101151062	Applicator for inserting an implant
Hong Kong	1096316	X-ray visible drug delivery device

Supplementary Protection Certificates for etonogestrel

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0303306	099C0041	Belgium		PRODUCT NAME: ETONOGESTREL; NATL. REGISTRATION NO/DATE: 52 IS 296 F 14 19990531; FIRST REGISTRATION: NL RVG 21168 19980825
0303306	SPC/GB99/044	United Kingdom		PRODUCT NAME: ETONOGESTREL; REGISTERED: NL RGV21168 19980825; UK 00065/0161 19990609
0303306	29/1999	Austria		PRODUCT NAME: ETONOGESTREL; NAT. REGISTRATION NO/DATE: 1-22964 19990330; FIRST REGISTRATION: NL 21168 19980825
0303306	C980027	Netherlands		PRODUCT NAME: ETONOGESTREL; REGISTRATION NO/DATE: RVG 21168 19980825

Etonogestrel: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Summary

Etonogestrel, a synthetic progestogen used primarily in contraceptive devices, has exhibited consistent growth driven by rising global demand for long-acting reversible contraception (LARC) and increasing awareness of family planning options. The market landscape involves key players including Merck, Teva Pharmaceuticals, and Mylan, with emerging biosimilar and innovative delivery systems expanding the scope.

This report analyzes the current investment environment, market drivers, key competitors, revenue forecasts, and regulatory considerations for etonogestrel-based products. It concludes with actionable insights for investors aiming to navigate this segment effectively.

---

What is Etonogestrel and How Is It Used in the Pharmaceutical Market?

Product Overview

Product Type	Usage	Delivery Method	Marketed Brands
Synthetic progestogen	Contraception	Implants, vaginal rings	Implanon/Nexplanon, NuvaRing
Primary Applications	Long-acting reversible contraception	-	-

Mechanism of Action

Etonogestrel inhibits ovulation, thickens cervical mucus, and thins the endometrial lining, providing highly effective contraception over extended durations (up to 3 years for implants, 1 month for vaginal rings).

---

Market Dynamics

Global Market Size and Growth Rate

Aspect	Data / Estimate	Source
Global etonogestrel-based contraceptive market (2022)	USD 1.9 billion	[1]
Compound Annual Growth Rate (CAGR)	5.8% (2023–2028)	[2]
Market forecast (2028)	USD 2.7 billion	[2]

Key Drivers

Driver	Explanation
Rising global awareness of family planning	Especially in Asia-Pacific and Latin America.
Increased approval of implants and rings	Expanding indications and consumer acceptance.
Technological innovations	Development of biodegradable implants, thinner rings.
Government policies	Support for contraceptive access, funding in low-resource regions.

Constraints

Constraint	Impact
Patent expirations	Increased competition from generics and biosimilars.
Regulatory hurdles	Varying approval processes globally.
Market saturation	Particularly in mature markets like North America.

---

Competitive Landscape

Leading Companies and Portfolio

Company	Product(s)	Market Share (%)	Notable Strategies
Merck (Organon)	Nexplanon (implant), NuvaRing	48% (estimated)*	R&D focus on innovative delivery systems.
Teva Pharmaceuticals	Implanon/Nexplanon, generic formulations	20%	Price competitiveness, biosimilars.
Mylan (now part of Viatris)	Generic etonogestrel rings	10%	Cost-effective variants.
Others	Developing biosimilar and new delivery methods	22%	Focused on emerging markets.

*Estimated based on industry reports [3]

Regulatory and Patent Status

Aspect	Status/Notes	Source
Patent expiration date	Nexplanon patent expired in 2019 (US)	[4]
Biosimilar approvals	Increasing, notably in Europe and Asia	[5]
Regulatory pathways	Vary by region—EMA, FDA, PMDA, etc.	[6]

---

Financial Trajectory and Revenue Forecasts

Historical Revenue

Year	Estimated Revenue (USD Million)	Source
2020	1,650	Industry Reports
2021	1,800	Industry Reports
2022	1,900	[1]

Projected Revenue (2023–2028)

Year	Forecasted Revenue (USD Million)	CAGR (%)	Assumptions
2023	2,020	5.8	Market recovery post-pandemic, continued adoption trends.
2024	2,150	6.4	Launch of biosimilar options in key markets.
2025	2,290	6.5	Expansion into emerging markets.
2026	2,440	6.6	Increasing penetration of implant-based contraceptives.
2027	2,600	6.5	Government grants, improved healthcare access.
2028	2,770	6.7	Innovation-driven market growth.

Revenue Contributors

Contributor	Estimated Share (%)	Key Notes
Established brands (e.g., Nexplanon, NuvaRing)	75%	Core revenue streams, high consumer awareness.
Biosimilars and generics	15%	Growing, especially in Europe and Asia.
New delivery systems	10%	R&D projects, pipeline products.

---

Regulatory Environment & Policy Impact

Region	Regulatory Status	Impact
North America (FDA)	Stringent approval process, patent protections.	Potential delays for biosimilars.
European Union (EMA)	Facilitates biosimilar entry, flexible pathways.	Entry of biosimilar competition expected.
Asia-Pacific	Rapid approvals, increasing generics/traditional use	Market expansion opportunities.
Low-resource Countries	Support for contraceptive access, subsidized schemes	Market growth in emerging economies.

Comparison with Similar Markets

Parameter	Etonogestrel Market	Levonorgestrel Market	Overall Contraceptive Market
Market size (2022)	USD 1.9 billion	USD 2.0 billion	USD 50 billion
CAGR (2023–2028)	5.8%	4.8%	6.2%
Key Delivery Form	Implants, Rings	Intrauterine Devices, Pills	Oral, Injectable, Devices
Main Innovators	Merck, Teva, Mylan	Bayer, Breakthrough Biosciences	Top pharmaceutical firms

---

FAQs

1. What are the primary growth opportunities for etonogestrel-based contraceptives?
Expanding into emerging markets, development of biosimilars, and innovation in delivery systems (e.g., biodegradable implants) present significant growth opportunities.

2. How will patent expirations affect the market?
Patent expirations, notably for Nexplanon in 2019 in the US, have allowed biosimilars and generic versions to enter, intensifying competition and exerting downward pressure on prices.

3. What regulatory challenges influence the market?
Varying global approval pathways, particularly for biosimilars, can delay market entry. Regulatory bodies prioritize safety and efficacy, requiring extensive clinical data.

4. Are biosimilars impacting the revenue outlook?
Yes. Biosimilars are projected to account for 15% of total revenue growth from 2023 onward, especially in Europe and Asia where regulatory policies are more accommodating.

5. What potential innovations could disrupt the current market?
Biodegradable and more discreet implants, ring devices with enhanced drug-release profiles, and combination products integrating contraception with other health benefits could reshape the landscape.

---

Key Takeaways

• The etonogestrel market is positioned for steady growth driven by expanding global acceptance of LARC methods.
• Major players include Merck, Teva, and Mylan, with biosimilar entrants increasing competition.
• Revenue is projected to reach USD 2.77 billion by 2028, with significant contributions from emerging markets.
• Patent expirations and regulatory landscapes will influence pricing, market entry, and innovation pipelines.
• Investment opportunities are strongest in biosimilars, delivery system innovations, and markets with underserved populations.

---

References

[1] Industry Reports, "Global Etonogestrel Market Analysis," 2022.

[2] Market Research Future, "Contraceptive Market Forecast 2023–2028," 2023.

[3] Statista, "Market Share of Leading Contraceptive Manufacturers," 2022.

[4] U.S. Patent and Trademark Office, "Nexplanon Patent Expiry," 2019.

[5] European Medicines Agency, "Biosimilar Contraceptives Approvals," 2022.

[6] WHO, "Regulatory Pathways for Contraceptive Devices," 2021.

---

This report is intended to equip investors and industry stakeholders with comprehensive insights into etonogestrel’s market landscape, competitive positioning, and financial outlook.